The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas

Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making long-term disease-free survival possible for selected groups of metas...

Full description

Bibliographic Details
Published in:Nowotwory
Main Authors: Konrad Zasadziński, Mateusz J. Spałek
Format: Article
Language:English
Published: Via Medica 2023-02-01
Subjects:
Online Access:https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/view/91895
_version_ 1849313136358719488
author Konrad Zasadziński
Mateusz J. Spałek
author_facet Konrad Zasadziński
Mateusz J. Spałek
author_sort Konrad Zasadziński
collection DOAJ
container_title Nowotwory
description Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making long-term disease-free survival possible for selected groups of metastatic sarcoma patients. Oligometastatic and oligoprogressive disease constitute such indications. Although the administration of stereotactic radiation therapy (SBRT) for sarcoma metastases has been continuously rising over the past years, the evidence for such treatment is relatively scarce, lacking in larger prospective randomized clinical trials, and there is no consensus regarding strict indications, patient selection, and the time order of multimodal treatment. In this article, we discuss available clinical data regarding the efficacy and safety of SBRT in oligometastatic and oligoprogressive sarcoma, highlighting its indications in specific organ sites, as well as the possible limitations of this treatment modality.
format Article
id doaj-art-e9d30b0f832d4ff48406e1facfbd4e1c
institution Directory of Open Access Journals
issn 0029-540X
2300-2115
language English
publishDate 2023-02-01
publisher Via Medica
record_format Article
spelling doaj-art-e9d30b0f832d4ff48406e1facfbd4e1c2025-09-03T08:14:34ZengVia MedicaNowotwory0029-540X2300-21152023-02-0173110.5603/NJO.a2022.0061The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomasKonrad Zasadziński0Mateusz J. Spałek1https://orcid.org/0000-0002-3960-7673Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandSarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making long-term disease-free survival possible for selected groups of metastatic sarcoma patients. Oligometastatic and oligoprogressive disease constitute such indications. Although the administration of stereotactic radiation therapy (SBRT) for sarcoma metastases has been continuously rising over the past years, the evidence for such treatment is relatively scarce, lacking in larger prospective randomized clinical trials, and there is no consensus regarding strict indications, patient selection, and the time order of multimodal treatment. In this article, we discuss available clinical data regarding the efficacy and safety of SBRT in oligometastatic and oligoprogressive sarcoma, highlighting its indications in specific organ sites, as well as the possible limitations of this treatment modality.https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/view/91895stereotactic body radiotherapysarcomametastaseshypofractionationradiotherapy
spellingShingle Konrad Zasadziński
Mateusz J. Spałek
The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
stereotactic body radiotherapy
sarcoma
metastases
hypofractionation
radiotherapy
title The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
title_full The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
title_fullStr The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
title_full_unstemmed The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
title_short The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
title_sort role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
topic stereotactic body radiotherapy
sarcoma
metastases
hypofractionation
radiotherapy
url https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/view/91895
work_keys_str_mv AT konradzasadzinski theroleofstereotacticbodyradiotherapyinthemanagementofoligometastaticsofttissueandbonesarcomas
AT mateuszjspałek theroleofstereotacticbodyradiotherapyinthemanagementofoligometastaticsofttissueandbonesarcomas
AT konradzasadzinski roleofstereotacticbodyradiotherapyinthemanagementofoligometastaticsofttissueandbonesarcomas
AT mateuszjspałek roleofstereotacticbodyradiotherapyinthemanagementofoligometastaticsofttissueandbonesarcomas